Ovarian lipid metabolic alterations in polycystic ovary syndrome: insights from proton magnetic resonance spectroscopy
Wang KY., Yang T., Ding YF., Zeng AR., Li Y., Qiang JW.
Cohort Study, published in Front Med (Lausanne) (2025) — summary generated from the PubMed abstract.
Early human evidence such as case series or small samples is exploring possible benefits.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Cohort Study
- Journal
- Front Med (Lausanne) (2025)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 41169416
- PMCID
- PMC12568718
- DOI
- 10.3389/fmed.2025.1652954
- Citations
- 1
Abstract (original English)
Objectives Altered ovarian lipid metabolism plays a critical role in the pathophysiology of polycystic ovary syndrome (PCOS). This study aimed to evaluate and compare ovarian lipid metabolic profiles in PCOS patients and healthy controls using proton magnetic resonance spectroscopy ( 1 H-MRS). Method This was a single-center prospective study. Single-voxel 1 H-MRS was used to identify the lipid metabolism in 50 PCOS patients and 40 healthy controls (training cohort). A total of 34 PCOS patients and 39 controls underwent 1 H-MRS on the contralateral ovaries (test cohort). Key lipid metabolites were identified and quantified using LCModel software. A combination of these key lipids using the binary logistic regression analysis was constructed to enhance the discrimination efficiency between PCOS patients and the controls. Results Significant elevations were observed in lipid metabolites MM09 + Lip09, MM14 + Lip13a + Lip13b + MM12, MM21 + Lip21, Lip23, and Lip28 (e.g., MM09, macromolecule signal at 0.9 ppm; Lip09, lipid signal at 0.9 ppm) in PCOS patients compared to controls. The combination model of key lipids achieved an AUC of 0.89 [95% confidence interval (CI): 0.83-0.95], with sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of 0.76, 0.95, 0.95, and 0.76, respectively, in the training cohort, and 0.88 (95% CI, 0.80-0.95), 0.76, 0.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
Evidence level
Early human evidence such as case series or small samples is exploring possible benefits.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.